Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

• Life sciences   Surgical dentistry  

Affiliation 【 display / non-display 】

Affiliation 【 display / non-display 】

• Sapporo Medical University   医学部   助教  

Papers 【 display / non-display 】

Papers 【 display / non-display 】

• 広範囲顎骨支持型補綴治療における当科での非可動粘膜獲得のための一工夫

  都倉 尭明, 出張 裕也, 西山 廣陽, 宮本 昇, 大橋 伸英, 佐々木 敬則, 宮崎 晃亘

  Japanese Journal of Maxillo Facial Implants ( (公社)日本顎顔面インプラント学会 )  22 ( 3 ) 177 - 177  2023.11

• Accurate estimation of skeletal muscle mass by comparison of computed tomographic images of the third lumbar and third cervical vertebrae in Japanese patients with oral squamous cell carcinoma.

  Nobuhide Ohashi, Kazushige Koike, Kurumi Sakai, Koyo Nishiyama, Takanori Sasaki, Kazuhiro Ogi, Hironari Dehari, Nobumichi Kobayashi, Akihiro Miyazaki

  Oral radiology   39 ( 2 ) 408 - 417  2022.09  [Domestic journal]

  　View Summary

  OBJECTIVES: We evaluated the accuracy of estimating the cross-sectional area (CSA) at the third lumbar vertebra (L3) based on the CSA at the third cervical vertebra (C3) using computed tomographic images, and we identified the sources of error and bias using the evaluation of absolute reliability in 89 Japanese patients with oral squamous cell carcinoma. METHODS: Skeletal muscle CSA was measured at the C3 and L3 on pretreatment computed tomographic images. We used the CSA at the C3 to estimate CSA at the L3 in an existing prediction formula. Correlation coefficients were used to evaluate the relative reliability of the estimate, and Bland-Altman analysis and minimum detectable change (MDC) were used to evaluate its absolute reliability. RESULTS: Estimated and actual CSAs at L3 were strongly correlated (r = 0.885, p < 0.001). The mean difference between the estimated and actual CSAs was - 1.0887 cm2, the 95% confidence interval was - 4.09 to 1.91 cm2 (p = 0.472), and the 95% limits of agreement were - 29.0 and 26.8 cm2. The MDC at the 95% level of confidence in estimated and actual CSAs was 27.9 cm2. CONCLUSIONS: The estimation of CSA at the L3 from the existing prediction formula with the CSA at the C3 had no systematic biases, but it did have random errors. Random errors resulted from measurement errors and biological variation. Usefulness of the existing formula is limited by physical differences in populations.

  DOI PubMed

• Clinical and histopathologic effects of neoadjuvant intra-arterial chemoradiotherapy with cisplatin in combination with oral S-1 on stage III and IV oral cancer

  Kazushige Koike, Nobuhide Ohashi, Koyo Nishiyama, Junya Okamoto, Takanori Sasaki, Kazuhiro Ogi, Hironari Dehari, Naoki Hirokawa, Masanori Someya, Masato Saito, Hiroki Okuda, Akemi Otani, Tomoko Sonoda, Taro Sugawara, Tadashi Hasegawa, Hiroyoshi Hiratsuka, Koh-Ichi Sakata, Akihiro Miyazaki

  ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY ( ELSEVIER SCIENCE INC )  134 ( 3 ) 347 - 353  2022.09

  　View Summary

  Objective. The aim of this study was to examine the clinical and histopathologic effects of neoadjuvant intra-arterial chemoradiotherapy (IACRT) using cisplatin in combination with oral S-1 (tegafur/gimeracil/oteracil potassium) on stage III and IV oral squamous cell carcinoma.Study design. Thirty patients received infusions of superselective intra-arterial cisplatin 60 mg/m(2) by the Seldinger method and conventional external beam radiotherapy (total 40 Gy) combined with oral S-1 on the day of irradiation. Curative surgery and neck dissection were performed 4 to 6 weeks after IACRT. The clinical response of the primary lesion was evaluated approximately 4 weeks after IACRT. The surgically resected specimens were examined for histologic features according to the grading system for histologic evaluation and for residual tumor grade (RGrades).Results. Histopathologic evaluation of the therapeutic effect was grade 2 in 10 patients and grade 3 in 16 patients. According to the distribution of RGrades, the remaining tumor cells were mostly in the central area of the primary lesion, as seen in 24 patients.Conclusions. These findings indicate that neoadjuvant IACRT with cisplatin and oral S-1 was an effective treatment, suggesting the possibility of reducing the extent of curative surgery based on RGrades.

  DOI

• Prognostic Value of CD45Ro+ T-Cell Expression in Patients With Oral Squamous Cell Carcinoma.

  Kazushige Koike, Koyo Nishiyama, Hironari Dehari, Kazuhiro Ogi, Takanori Sasaki, Shota Shimizu, Takashi Sasaya, Kei Tsuchihashi, Tomoko Sonoda, Tadashi Hasegawa, Hiroyoshi Hiratsuka, Akihiro Miyazaki

  Anticancer research   41 ( 9 ) 4515 - 4522  2021.09  [International journal]

  　View Summary

  BACKGROUND/AIM: The role of tumour-infiltrating CD45Ro+ T-cells in oral squamous cell carcinoma (OSCC) is unclear. This study aimed to evaluate prognostic biomarkers for OSCC. PATIENTS AND METHODS: We determined the density of tumour-infiltrating CD45Ro+ T cells in the parenchyma and stroma at the tumour centre (TCe) and invasive front (IF) and examined the association between the density of these cells and histopathological status in 142 patients. RESULTS: Five-year overall survival (OS) and recurrence-free survival were favourable in patients with high CD45Ro+ T-cell density in the TCe stroma. OS was favourable in patients with high CD45Ro+ T-cell density in the IF stroma. Stepwise Cox regression model analysis indicated that CD45Ro+ T-cells in the stroma of the IF and TCe were an independent prognostic factor for OS. CONCLUSION: CD45Ro+ T-cells in the stroma of the IF and TCe play a role in cancer immune surveillance and may be a useful prognostic factor.

  DOI PubMed

• 当院における周術期等口腔機能管理の臨床統計的検討

  上野 智史, 小池 和茂, 土橋 恵, 笹谷 聖, 西山 廣陽, 大西 みちよ, 中井 裕美, 上田 愛, 佐々木 敬則, 三木 善樹, 高橋 ゆかり, 水野 愛理, 種村 理絵子, 荻 和弘, 出張 裕也, 宮崎 晃亘

  日本口腔ケア学会雑誌 ( (一社)日本口腔ケア学会 )  14 ( 3 ) 199 - 199  2020.09

display all >>

Misc 【 display / non-display 】

Misc 【 display / non-display 】

• A case of SAPHO syndrome diagnosed due to pain after implant treatment

  宮本昇, 宮本昇, 出張裕也, 西山廣陽, 佐々木敬則, 五十嵐友彦, 五十嵐友彦, 志村俊一, 志村俊一, 都倉尭明, 都倉尭明, 中村博幸, 宮崎晃亘

  Japanese Journal of Maxillo Facial Implants   20 ( 4 )  2021

  J-GLOBAL

• Stage III・IVの口腔扁平上皮癌に対する動注化学療法併用放射線治療の治療効果に関する検討

  小池和茂, 岡本準也, 西山廣陽, 佐々木敬則, 荻和弘, 出張裕也, 宮崎晃亘

  頭頸部癌   47 ( 2 )  2021

  J-GLOBAL

• ハイドロゲル創傷被覆・保護剤エピシルが口腔粘膜炎患者の経口摂取に及ぼす影響

  水野 愛理, 巽 博臣, 佐々木 敬則, 仲 詩織, 荒川 朋子, 藤井 由美子, 石崎 千順, 大原 雄希, 梅森 祥央, 黒川 翔, 秋月 恵美, 信岡 隆幸, 宮崎 晃亘

  学会誌JSPEN ( (一社)日本臨床栄養代謝学会 )  2 ( Suppl.1 ) 1492 - 1492  2020.11

• リハビリテーション治療の効果を高める栄養管理-個別対応と組織的対応- 集中治療と、栄養療法と、リハビリテーション治療と ICUとNSTをやってわかったこと

  巽 博臣, 井山 諭, 大槻 郁人, 宮城島 沙織, 清藤 恭貴, 黒川 翔, 大原 雄希, 高橋 和也, 望月 真希, 石原 悦菜, 仲 詩織, 白石 沙耶可, 荒川 朋子, 藤井 由美子, 水野 愛理, 佐々木 敬則, 原田 敬介, 信岡 隆幸, 升田 好樹

  The Japanese Journal of Rehabilitation Medicine ( (公社)日本リハビリテーション医学会 )  57 ( 特別号 ) S434 - S434  2020.07

• 上顎骨肉腫治療後の顎欠損に対して腓骨再建し広範囲顎骨支持型補綴装置を応用した1例

  宮本昇, 出張裕也, 五十嵐友彦, 佐々木敬則, 佐々木敬則, 志村俊一, 西山廣陽, 都倉尭明, 宮崎晃亘

  Japanese Journal of Maxillo Facial Implants   17 ( 3 ) 257  2018.11

  J-GLOBAL

display all >>

Awards 【 display / non-display 】

Awards 【 display / non-display 】

• 若手研究奨励賞

  2011   日本がん免疫学会  

Research Projects 【 display / non-display 】

Research Projects 【 display / non-display 】

• Elucidation of the mechanisms relating to immunoregulation in oral tumor microenvironment and development of novel treatments

  Grant-in-Aid for Scientific Research (B)

  Project Year :

  2023.04

  -

  2026.03

   

  宮崎 晃亘, 佐々木 敬則, 宮本 昇, 笹谷 聖, 加藤 大貴

• 口腔がん免疫療法に抗NKG2A抗体を併用した新たな機能温存治療の開発

  若手研究

  Project Year :

  2020.04

  -

  2023.03

   

  佐々木 敬則

  　View Summary

  令和3年度は口腔がん患者の組織検体でHLA-EおよびNKG2Aの免疫染色を行った。現在、解析を行っている。また樹立した癌細胞株のHLA-E発現とTILのNKG2A発現をフローサイトメトリーで確認し、解析を行っている。

• Basic and clinical study of new peptide vaccine therapy for patients with oral cancer

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2013.04

  -

  2016.03

   

  Miyazaki Akihiro, KOBAYASHI Jun-ichi, SASAKI Takanori, FUJINO Junki, MICHIFURI Yoshitaka

  　View Summary

  We described a sequential clinical trial of SVN-2B peptide vaccine therapy in combination with incomplete Freund’s adjuvant (IFA) and interferon (IFN)-alpha for patients with oral cancer. Results indicated that the combination therapy increased the frequency of peptide specific cytotoxic T lymphocytes (CTLs) more effectively than the peptide alone. This regimen may be useful as a new therapeutic modality. We isolated oral cancer stem-like cells (CSCs) as aldehyde dehydrogenase 1 bright (ALDH1br) cells. SPRR1B gene was shown to be overexpressed in the ALDH1br cells, indicating that it has a role in cell growth and maintenance by suppression of RASSF4. Furthermore, we established an oral cancer cell line and an autologous CTL line. It was shown that the CTL line recognized autologous tumor cells in an HLA-A24-restricted manner. Precise analyses of the CTL-recognized antigens may provide us with substantial strategies toward developing a more effective cancer peptide vaccine.

• Analysis of the β catenin gene abnormality and therapeutic application for oral cancer.

  Grant-in-Aid for Scientific Research (B)

  Project Year :

  2010

  -

  2012

   

  HIRATSUKA Hiroyoshi, DEHARI Hironari, MIYAZAKI Akihiro, OGI Kazuhiro, SASAKI Takanori, NAKAMORI Kenji, KOBAYASHI Jyunichi, SOGABE Youhei, YAMAMOTO Takashi, SHIMANISHI Makoto

  　View Summary

  Hypoxic regions in solid tumors mediate malignant transformation, cancer cell proliferation, resistance to anti-cancer agents, and enhanced cellular invasion and metastasis. In this study, we found that the wnt/β-catenin pathway activation mediates the acquisition of invasion and metastatic potential in oral squamous cell carcinoma cells. Hypoxia enhances the expression of glucose transporter 1 (GLUT1) and anticancer drug resistance, and activates NF-κB/p65 to trigger cell proliferation.

• Development of cancer peptide vaccine therapy for oral cancer

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2010

  -

  2012

   

  MIYAZAKI Akihiro, YAMAGUCHI Akira, KOBAYASHI Jyunichi, YAMAMOTO Takashi

  　View Summary

  We have confirmed the safety and efficacy of a cancer peptide vaccine therapy using a survivin2B-derived peptide decomposed from a survivin protein that is highly expressed in many malignancies. Furthermore, a clinical trial indicated that when using the peptide in conjunction with stimulants, a stronger immune effect could be obtained than from the peptide alone. The trial also confirmed the safety of the vaccine therapy. In the quest to develop a cancer peptide vaccine other than survivin, we have identified molecules that are highly expressed in cancer stem cells of the oral cavity, and established a foundation towards a more effective clinical application of cancer peptide vaccine therapy.